Mereo BioPharma completes patient enrollment for BPS-804 Phase 2b trial in osteogenesis imperfecta
British specialty biopharma company Mereo BioPharma Group has completed patient enrollment for a Phase 2b clinical trial of its human monoclonal antibody BPS-804, also known as Setrusumab. This trial aims to evaluate BPS-804 as a potential treatment for osteogenesis imperfecta (OI), commonly referred to as brittle bone disease. Osteogenesis imperfecta is a rare genetic disorder […]